Last reviewed · How we verify
Olmesartan/amlodipine
Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
This combination blocks angiotensin II receptors (olmesartan) and calcium channels (amlodipine) to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension.
At a glance
| Generic name | Olmesartan/amlodipine |
|---|---|
| Also known as | Sevikar (r) |
| Sponsor | Institut für Pharmakologie und Präventive Medizin |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (CCB). Olmesartan prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced contractility. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (PHASE4)
- Multi-Omics to Predict the Blood Pressure Response to Antihypertensives (PHASE4)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olmesartan/amlodipine CI brief — competitive landscape report
- Olmesartan/amlodipine updates RSS · CI watch RSS
- Institut für Pharmakologie und Präventive Medizin portfolio CI